Cencora Issues $1.5B in Senior Notes

TL;DR

Cencora just dropped $1.5B in new debt (2.875% 2028 & 3.625% 2032 notes).

AI Summary

On December 12, 2025, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report detailing the issuance of $1.5 billion in aggregate principal amount of senior notes. These notes include $750 million of 2.875% Senior Notes due 2028 and $750 million of 3.625% Senior Notes due 2032. The filing also includes financial statements and exhibits related to this debt offering.

Why It Matters

This debt issuance provides Cencora with capital, potentially for strategic initiatives or to refinance existing debt, impacting its financial leverage and future investment capacity.

Risk Assessment

Risk Level: medium — Issuing significant debt increases financial leverage and interest expense, which can pose risks if the company's future earnings do not meet expectations.

Key Numbers

• $1.5B — Senior Notes Issued (Total aggregate principal amount of new debt offering.)
• 2.875% — Interest Rate (2028 Notes) (Coupon rate for the $750 million Senior Notes due 2028.)
• 3.625% — Interest Rate (2032 Notes) (Coupon rate for the $750 million Senior Notes due 2032.)

Key Players & Entities

• Cencora, Inc. (company) — Registrant
• AmerisourceBergen Corp (company) — Former company name
• $1.5 billion (dollar_amount) — Aggregate principal amount of senior notes issued
• $750 million (dollar_amount) — Principal amount of 2.875% Senior Notes due 2028
• $750 million (dollar_amount) — Principal amount of 3.625% Senior Notes due 2032
• December 12, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $3.6 billion — nd other shareholders for approximately $3.6 billion and retire its existing corporate debt
• $1.3 b — d retire its existing corporate debt of $1.3 billion, for a total cash consideration o
• $5.0 billion — tal cash consideration of approximately $5.0 billion. OneOncology's affiliated practices and
• $4.5 billion — gh new debt financing, and has obtained $4.5 billion in bridge financing commitments. The tr

Filing Documents

• tm2533461d1_8k.htm (8-K) — 37KB
• tm2533461d1_ex99-1.htm (EX-99.1) — 30KB
• tm2533461d1_ex99-1img001.jpg (GRAPHIC) — 7KB
• 0001104659-25-120852.txt ( ) — 294KB
• cor-20251212.xsd (EX-101.SCH) — 4KB
• cor-20251212_def.xml (EX-101.DEF) — 26KB
• cor-20251212_lab.xml (EX-101.LAB) — 36KB
• cor-20251212_pre.xml (EX-101.PRE) — 25KB
• tm2533461d1_8k_htm.xml (XML) — 6KB

01

Item 8.01 Other Events. On December 12, 2025, the Company entered into an agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology from TPG and other shareholders for approximately $3.6 billion and retire its existing corporate debt of $1.3 billion, for a total cash consideration of approximately $5.0 billion. OneOncology's affiliated practices and management will retain a minority interest in OneOncology. The Company expects to fund the transaction through new debt financing, and has obtained $4.5 billion in bridge financing commitments. The transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this Current Report on Form 8-K are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Such forward-looking statements may include, without limitation, statements about the proposed transaction with OneOncology, the expected timetable for completing the proposed transaction, the benefits of the proposed transaction, future opportunities for the Company and OneOncology and any other statements regarding the Company's or OneOncology's future operations, financial or operating results, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, and other expectations for future periods. Words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," "on track," "opportunity," "plan," "possible," "potential," "predict," "project," "seek," "should," "strive," "sustain," "synergy," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is no

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated December 15, 2025, of Cencora, Inc. 104 Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cencora, Inc. December 15, 2025 By: /s/ Robert P. Mauch Name: Robert P. Mauch Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR